Georgetown University School of Medicine, Washington, USA.
Department of Neurological Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, USA.
Ann Oncol. 2021 Aug;32(8):968-982. doi: 10.1016/j.annonc.2021.03.197. Epub 2021 Mar 24.
Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers, such as lung cancer and melanoma, immunotherapeutics has emerged as a major player in the potential treatment of gliomas, with oncolytic viruses in particular showing significant promise as evidenced by the recent Breakthrough and Fast Tract Designations for PVSRIPO and DNX2401. This review serves as a useful and updated compendium of the completed human clinical investigations for several oncolytic viruses in the treatment of gliomas.
神经胶质瘤仍然是肿瘤治疗中更令人沮丧的目标之一。神经胶质瘤对传统疗法的耐药性是其在血脑屏障后面的免疫特权环境的产物，此外，它们对免疫反应本身也有抑制作用。从肺癌和黑色素瘤等系统性癌症的免疫治疗日益成功中吸取经验，免疫疗法已成为治疗神经胶质瘤的主要手段之一，特别是溶瘤病毒，最近 PVSRIPO 和 DNX2401 获得突破性和快速通道指定，证明了其具有显著的潜力。本综述是对几种溶瘤病毒治疗神经胶质瘤的已完成人体临床研究的有用且最新的汇编。
